rhASM + rhASM + rhASM + rhASM + rhASM
Phase 1Terminated 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acid Sphingomyelinase Deficiency
Conditions
Acid Sphingomyelinase Deficiency, Niemann-Pick Disease
Trial Timeline
Dec 1, 2006 → Apr 1, 2009
NCT ID
NCT00410566About rhASM + rhASM + rhASM + rhASM + rhASM
rhASM + rhASM + rhASM + rhASM + rhASM is a phase 1 stage product being developed by Sanofi for Acid Sphingomyelinase Deficiency. The current trial status is terminated. This product is registered under clinical trial identifier NCT00410566. Target conditions include Acid Sphingomyelinase Deficiency, Niemann-Pick Disease.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00410566 | Phase 1 | Terminated |
Competing Products
20 competing products in Acid Sphingomyelinase Deficiency
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Low Dose REN001 + High Dose REN001 | OnKure Therapeutics | Phase 1 | 25 |
| ONO-8539 | Ono Pharmaceutical | Phase 1 | 33 |
| LJN452 + Placebo to LJN452 | Novartis | Phase 2 | 52 |
| Insulin (Aspart Insulin [Novolog], Regular Insulin) | Novo Nordisk | Pre-clinical | 22 |
| Pantoprazole | Pfizer | Approved | 84 |
| Recombinant human acid sphingomyelinase | Sanofi | Phase 1 | 32 |
| Olipudase alfa | Sanofi | Pre-clinical | 22 |
| insulin glargine+ glulisine + NPH + Regular insulin | Sanofi | Approved | 84 |
| Ataluren | Sanofi | Phase 2 | 51 |
| Omeprazole/sodium bicarbonate + omeprazole magnesium + sodium bicarbonate | Bayer | Phase 3 | 74 |
| Omeprazole/sodium bicarbonate + omeprazole magnesium (20 mg equivalent) | Bayer | Phase 3 | 74 |
| Zegerid + Prilosec OTC™ Tablets | Bayer | Phase 3 | 74 |
| A3384 | Ipsen | Phase 2 | 49 |
| Clinolipid + Intralipid | Baxter | Approved | 82 |
| Clinolipid + Intralipid | Baxter | Approved | 82 |
| Carglumic Acid | Recordati | Pre-clinical | 20 |
| Cholic acid | Mirum Pharmaceuticals | Phase 3 | 74 |
| AAV2-hAADC | PTC Therapeutics | Phase 2 | 49 |
| gene therapy | PTC Therapeutics | Phase 1/2 | 38 |
| Cholbam | Mirum Pharmaceuticals | Pre-clinical | 20 |